Merck & Co.
AWARDS
NEWS
It looks to be a pretty busy week for the U.S. Food and Drug Administration (FDA), with a number of target action dates for various drugs. Some were delayed, and some were already approved, but there are still a number on the schedule. Here’s a look.
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. The two-drug combination is capable of suppressing HIV for months at a time, according to a study published by The Rockefeller University.
Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.
Merck and Co., like many large corporations, has a mandatory retirement age of 65 for its chief executive officer. Today the company announced its board of directors and rescinded the policy to allow its current chief executive officer, Kenneth C. Frazier, stay on beyond his 65th birthday in December 2019.
This morning, Genentech released results of its Phase III IMpower 133 trial that showed treatment with Tecentriq plus chemotherapy helped people with extensive-stage small cell lung cancer live significantly longer than with chemotherapy alone.
JOBS
IN THE PRESS